Loxo Oncology, Inc
LOXO
LOXO was delisted on the 14th of February, 2019.
148 hedge funds and large institutions have $2.77B invested in Loxo Oncology, Inc in 2017 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 56 increasing their positions, 44 reducing their positions, and 14 closing their positions.
143% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 14
27% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 44
16% more capital invested
Capital invested by funds: $2.4B → $2.77B (+$377M)
15% more funds holding
Funds holding: 129 → 148 (+19)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
29% less call options, than puts
Call options by funds: $8.15M | Put options by funds: $11.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$41.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$32.6M |
| 4 |
BlackRock
New York
|
+$19.4M |
| 5 |
Renaissance Technologies
New York
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
-$51.6M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$28.3M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$21.6M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$21.5M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$19M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PC
151
PointState Capital
New York
| – | -$3.99M | -49,800 | Closed |
|
|
EU
152
Emory University
Atlanta,
Georgia
| – | -$2.74M | -34,143 | Closed |
|
|
QIM
153
Quantitative Investment Management
Charlottesville,
Virginia
| – | -$2.09M | -26,100 | Closed |
|
154
Two Sigma Investments
New York
| – | -$1.77M | -22,052 | Closed |
|
|
MIM
155
Monashee Investment Management
Boston,
Massachusetts
| – | -$1.2M | -15,000 | Closed |
|
|
GAMA
156
Graticule Asia Macro Advisors
New York
| – | -$1.12M | -14,000 | Closed |
|
|
HI
157
HBK Investments
Dallas,
Texas
| – | -$556K | -6,933 | Closed |
|
158
Squarepoint
New York
| – | -$525K | -6,553 | Closed |
|
|
EMG
159
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$265K | -3,300 | Closed |
|
|
ARTA
160
A.R.T. Advisors
New York
| – | -$208K | -2,600 | Closed |
|
161
Creative Planning
Overland Park,
Kansas
| – | -$38K | -471 | Closed |
|
162
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$16K | -200 | Closed |
|
LOXO Hedge Fund Activity: Q3 2017 in Review
148 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q3 2017, worth a combined $2.77B — up 16% from $2.4B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new LOXO positions and 14 closed out — a net gain of 20 holders — while 56 added to existing stakes and 44 trimmed.
The largest buyer was Columbia Wanger Asset Management, opening a new position worth an estimated $41.5M. The largest seller was Paulson & Co, cutting an estimated $51.6M.
- 148 institutional investors held Loxo Oncology, Inc (LOXO) as of Q3 2017, up from 129 in Q2 2017.
- Funds reported $2.77B of Loxo Oncology, Inc stock for Q3 2017, up 16% quarter-over-quarter.
- 34 funds opened new Loxo Oncology, Inc positions in Q3 2017 and 14 closed out, a net change of +20 holders.
- The largest Loxo Oncology, Inc buyer in Q3 2017 was Columbia Wanger Asset Management, an estimated $41.5M added.
- The largest Loxo Oncology, Inc seller in Q3 2017 was Paulson & Co, an estimated $51.6M sold.
Based on aggregated 13F filings for Q3 2017.